CD38 and Miyoshi myopathy: We chose the therapeutic monoclonal daratumumab (anti-CD38 IgG Kappa) as the initial target because IgG Kappa represents the most prevalent M-Ig isotype in MM, and because serum samples from MM patients obtained pre-and post daratumumab treatment provided the relevant validation matrix.